NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Drug Manufacturers - Specialty & Generic · CAD

Canopy Growth Corporation (WEED.TO) Stock Analysis

Canopy Growth Corporation (WEED.TO) is a Drug Manufacturers - Specialty & Generic stock listed on TSX and quoted in Canadian Dollar.

WEED.TO

CA$1.35

CA$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare WEED.TO with… →

WEED.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$1.34
Previous Close
CA$1.35
Day's Range
1.33–1.36
52-Week Range
1.18–3.28
Volume
277.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.43
Valuation
Market Cap
CA$642.01M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.19
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.67
Financials (FY)
Revenue (FY)
CA$284.60M+5.80%
Net Income (FY)
−CA$262.91M
Profit marginThe share of revenue left as profit after all costs and taxes.
−79.22%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
423.04M
1-Year Return
−29.32%
Dividend and dates
Earnings Date
November 6, 2026estimated
Avg Volume
952.44K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

WEED.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−13.46%
2025−60.41%
2024−41.72%
2023−78.47%
2022−71.56%
2021−64.75%
2020+14.68%
2019−25.40%
2018+23.10%
2017+225.38%
2016 (partial year)+134.96%

As of September 4, 2026.

WEED.TO Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025CA$284.60M−CA$262.91M−92.4%
2024CA$269.00M−CA$508.88M−189.2%
2023CA$297.15M−CA$693.68M−233.4%
2022CA$333.25M−CA$3.28B−983.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$284.60MCA$69.67M−CA$73.11M−CA$262.91M−92.4%
2024CA$269.00MCA$79.51M−CA$66.39M−CA$508.88M−189.2%
2023CA$297.15MCA$80.88M−CA$162.73M−CA$693.68M−233.4%
2022CA$333.25M−CA$63.53M−CA$395.78M−CA$3.28B−983.7%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

WEED.TO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricWEED.TODrug Manufacturers - Specialty & Generic medianvs median
P/S ratio2.192.305% below
Profit margin−79.22%−3.14%76.1 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Canopy Growth Corporation (WEED.TO) carries a market capitalisation of CA$642.01M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 1,128 employees.

Over the past 52 weeks the price has ranged from CA$1.18 to CA$3.28. WEED.TO last closed at CA$1.35 on September 4, 2026. The close was unchanged from the previous session. The latest close sits 14.41% above that 52-week low.

Financial Health

In fiscal 2025, Canopy Growth Corporation reported revenue of CA$284.60M. That is +5.80% against the prior fiscal year, when revenue was CA$269.00M. The same year closed with a net loss of CA$262.91M. Profit margin runs at −79.22%. That is 76.1 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −0.67.

Across the 4 fiscal years on file, revenue moves from CA$333.25M in 2022 to CA$284.60M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 2.19 times revenue. On price-to-sales that is 4.78% below the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 2.43. Annualized volatility over the trailing 10 years is 102.06%. The trailing one-year price return is −29.32%. Measured over 10 years, that is −28.40% a year compounded.

Growth & Income

The record shows no dividend for WEED.TO.

The strongest complete calendar year on file is 2017 at +225.38%; the weakest is 2023 at −78.47%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −13.46% year to date.

Peer Comparison

Canopy Growth Corporation (WEED.TO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Canopy Growth Corporation WEED.TO CA$642.01M —
Takeda Pharmaceutical Company Limited TAK CA$58.92B —
Teva Pharmaceutical Industries Limited TEVA CA$42.37B 60.6
Haleon plc HLN CA$42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Canopy Growth Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Canopy Growth Corporation

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel. It also provides vaporizers and accessories; dried flower and pre-rolled joints, oil, and vapes and beverages; extracts and concentrates, such as softgel capsules; and cannabis edibles, including gummies. In addition, the company operates e-commerce shop; medical cannabis online distribution platform; and an online medical cannabis clinic. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Abba Medix, Storz & Bickel, Wana, and Claybourne, Apollo, Canada House, R'belle, LowKey, MTL Cannabis, DeeLish, DOJA brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Visit website →